Literature DB >> 1606086

Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography.

F M Muggia1, E LePoidevin, S Jeffers, C Russell, W Boswell, C P Morrow, J Curtin, J Schlaerth.   

Abstract

Nineteen patients with ovarian cancer and minimal residual or persistent disease who were treated with cisplatin or carboplatin-based intraperitoneal (IP) regimens had distribution studies of IP contrast and computerized tomography prior to and during treatment. The distribution pattern was assessed retrospectively and scored for the presence of contrast in each of eight regions: the under surface of right and left diaphragms, the right and left paracolic gutters, the lesser omental sac, the intramesenteric region and the true and false pelvis. Assigning a point to each region with adequate distribution, we classified 10 patients to an excellent pattern (greater than or equal to 7 of 8 regions), 6 to a good pattern (5 to less than 7 regions), and 3 to an inadequate distribution pattern (less than 5 regions). Serial studies were performed in 8 patients after more than 4 cycles of IP therapy. In these patients, all of whom were tolerating treatment without progression, the distribution remained virtually unchanged for those with excellent distribution. One of three with good distribution manifested inadequate distribution on repeat study, and one of two with inadequate distribution improved to show a good pattern. In this small study there was no correlation of distribution patterns with plasma CA-125 at onset of IP treatment and prior surgical procedures or placement of the catheter tip. However, three patients with unsatisfactory patterns had procedures consisting of catheter placement only rather than formal reassessment laparotomies for ovarian cancer. Since satisfactory IP distribution may be required for obtaining a therapeutic advantage from IP therapy, methods for its assessment must be developed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1606086     DOI: 10.1093/oxfordjournals.annonc.a058132

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  4 in total

1.  Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.

Authors:  Elliot Newman; Stuart G Marcus; Milan Potmesil; Sanjeev Sewak; Herman Yee; Joan Sorich; Mary Hayek; Franco Muggia; Howard Hochster
Journal:  J Gastrointest Surg       Date:  2002 Mar-Apr       Impact factor: 3.452

2.  Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance.

Authors:  F M Muggia; A Tulpule; A Retzios; F Chen; S Jeffers; C G Leichman; L Leichman; C P Spears; K K Chan
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study.

Authors:  V K Israel; C Jiang; F M Muggia; A Tulpule; S Jeffers; L Leichman; C P Morrow; L Roman; C G Leichman; K K Chan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.

Authors:  Joshua C Leinwand; Binsheng Zhao; Xiaotao Guo; Saravanan Krishnamoorthy; Jing Qi; Joseph H Graziano; Vesna N Slavkovic; Gleneara E Bates; Sharyn N Lewin; John D Allendorf; John A Chabot; Lawrence H Schwartz; Robert N Taub
Journal:  Ann Surg Oncol       Date:  2013-05-24       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.